AllSight
Companies · ACHV · In Vitro & In Vivo Diagnostic Substances

ACHIEVE LIFE SCIENCES, INC. (ACHV)

ACHIEVE LIFE SCIENCES, INC. (ACHV) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

ACHIEVE LIFE SCIENCES, INC. (ACHV) stock — financials & valuation

Key numbers for ACHIEVE LIFE SCIENCES, INC. (ACHV): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 51/100 — a percentile rank of ACHIEVE LIFE SCIENCES, INC.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.

Market cap$832.5M
EV / EBITDA-13.8×
Return on equity777.1%
ROIC123.2%
Debt / equity-1.0×
Dividend yield0.0%

Independent of the events above — derived from ACHIEVE LIFE SCIENCES, INC.’s own financial statements and shown as context, never as advice.

Oct 1, 2026CFO transition
Achieve Life Sciences names new CFO amid cytisinicline’s commercialization push
Aug 14, 2026$150M ATM program
$150M ATM gives the biotech cash flexibility—and shareholders dilution risk
Aug 11, 2026
Financing is secured, but FDA approval remains a 2027 catalyst
Related companies in In Vitro & In Vivo Diagnostic Substances
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact